Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1979 Sep;37(3):381-90.

Circulating immune complexes in patients with cryptogenic fibrosing alveolitis

Circulating immune complexes in patients with cryptogenic fibrosing alveolitis

P L Haslam et al. Clin Exp Immunol. 1979 Sep.

Abstract

Increased Clq binding levels have been obtained in serum from twenty-one (50%) of forty-two patients with cryptogenic fibrosing alveolitis (CFA) suggesting the presence of circulating immune complexes. There was a low frequency of positive results using a number of other tests for circulating immune complexes. The increased Clq binding levels were observed in six (35%) out of seventeen patients with lone lung involvement and in fifteen (60%) out of twenty-five patients with extrapulmonary connective tissue disorders. There was an especially close correlation between arthritis and elevated Clq binding. A strong correlation between Clq binding levels and levels of circulating rheumatoid factor (RF) and IgG, and enhancement in macrophage radiobioassay tests using RF-containing sera, suggested that RF might be involved in the circulating immune complexes in these patients. DNAase pre-treatment of sera did not influence the findings, and there was no correlation between Clq binding and levels of immunofluorescent ANA, C-reactive protein levels, or platelet counts. A weak correlation between Clq binding and erythrocyte sedimentation rates, and slightly lower binding levels in treated than untreated patients with 'lone' CFA suggested that binding levels may give some indication of disease activity and may in some instances be influenced by treatment.

PubMed Disclaimer

References

    1. Br Med J. 1965 Apr 3;1(5439):886-91 - PubMed
    1. Br Med J. 1964 Sep 12;2(5410):686 - PubMed
    1. Nature. 1962 May 5;194:495-6 - PubMed
    1. Ann Intern Med. 1976 Dec;85(6):769-88 - PubMed
    1. J Clin Invest. 1976 Nov;58(5):1223-32 - PubMed

LinkOut - more resources